| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Neil Osheroff | Q88626020 |
| P2093 | author name string | Robert J Kerns | |
| Katie J Aldred | |||
| P2860 | cites work | DNA topoisomerases: structure, function, and mechanism | Q22065417 |
| DNA gyrase, topoisomerase IV, and the 4-quinolones | Q24643546 | ||
| Emerging mechanisms of fluoroquinolone resistance | Q24644842 | ||
| Plasmid-mediated quinolone resistance: a multifaceted threat | Q24645356 | ||
| Structural basis of gate-DNA breakage and resealing by type II topoisomerases | Q27324504 | ||
| Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases | Q27655501 | ||
| A novel and unified two-metal mechanism for DNA cleavage by type II and IA topoisomerases | Q27661756 | ||
| Type IIA topoisomerase inhibition by a new class of antibacterial agents | Q27663884 | ||
| Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance | Q27664216 | ||
| Structural insights into quinolone antibiotic resistance mediated by pentapeptide repeat proteins: conserved surface loops direct the activity of a Qnr protein from a Gram-negative bacterium | Q27666560 | ||
| Mechanisms for Defining Supercoiling Set Point of DNA Gyrase Orthologs: II. THE SHAPE OF THE GyrA SUBUNIT C-TERMINAL DOMAIN (CTD) IS NOT A SOLE DETERMINANT FOR CONTROLLING SUPERCOILING EFFICIENCY | Q27678250 | ||
| The quinolones: decades of development and use | Q28191758 | ||
| DNA topoisomerases and their poisoning by anticancer and antibacterial drugs | Q28284744 | ||
| Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents | Q28306539 | ||
| Topoisomerase IV, alone, unknots DNA in E. coli | Q28361527 | ||
| Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding | Q33556083 | ||
| Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase | Q33556397 | ||
| Topoisomerase IV is a target of quinolones in Escherichia coli | Q33724600 | ||
| Mode of action of fluoroquinolones | Q33770059 | ||
| Interaction of the plasmid-encoded quinolone resistance protein QnrA with Escherichia coli topoisomerase IV | Q33883611 | ||
| The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold | Q33904609 | ||
| Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis | Q33980255 | ||
| Efflux pumps as antimicrobial resistance mechanisms | Q34003782 | ||
| Mechanism of plasmid-mediated quinolone resistance | Q34025874 | ||
| The use of divalent metal ions by type II topoisomerases. | Q34054930 | ||
| Mechanisms of action of antimicrobials: focus on fluoroquinolones | Q34183520 | ||
| Type II topoisomerases as targets for quinolone antibacterials: turning Dr. Jekyll into Mr. Hyde | Q34187326 | ||
| Fluoroquinolone prescribing in the United States: 1995 to 2002. | Q34399799 | ||
| The worldwide emergence of plasmid-mediated quinolone resistance | Q34569740 | ||
| Phylogenomics of DNA topoisomerases: their origin and putative roles in the emergence of modern organisms | Q34604464 | ||
| Use of divalent metal ions in the DNA cleavage reaction of topoisomerase IV. | Q35040946 | ||
| Mechanism of action of nalidixic acid: Purification of Escherichia coli nalA gene product and its relationship to DNA gyrase and a novel nicking-closing enzyme | Q35059616 | ||
| Nalidixic acid resistance: A second genetic character involved in DNA gyrase activity | Q35059655 | ||
| Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China | Q35102456 | ||
| Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance | Q35682250 | ||
| Mechanisms for defining supercoiling set point of DNA gyrase orthologs: I. A nonconserved acidic C-terminal tail modulates Escherichia coli gyrase activity | Q36002874 | ||
| New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate | Q36094929 | ||
| The quinolones: past, present, and future | Q36155438 | ||
| Mechanisms of resistance to quinolones | Q36155441 | ||
| Escherichia coli Mutants Thermosensitive for Deoxyribonucleic Acid Gyrase Subunit A: Effects on Deoxyribonucleic Acid Replication, Transcription, and Bacteriophage Growth | Q36311967 | ||
| Isolation and quantitation of topoisomerase complexes accumulated on Escherichia coli chromosomal DNA. | Q36364221 | ||
| Origin and evolution of DNA topoisomerases | Q36733344 | ||
| Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance | Q36783606 | ||
| Quinolone-mediated bacterial death. | Q36921143 | ||
| Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France | Q36932963 | ||
| DNA Topology and Topoisomerases: Teaching a "Knotty" Subject | Q37098901 | ||
| Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection | Q37101552 | ||
| The DNA cleavage reaction of topoisomerase II: wolf in sheep's clothing | Q37108461 | ||
| oqxAB encoding a multidrug efflux pump in human clinical isolates of Enterobacteriaceae | Q37274700 | ||
| Ciprofloxacin treatment failure in a murine model of pyelonephritis due to an AAC(6')-Ib-cr-producing Escherichia coli strain susceptible to ciprofloxacin in vitro. | Q37335894 | ||
| Overcoming target-mediated quinolone resistance in topoisomerase IV by introducing metal-ion-independent drug-enzyme interactions. | Q37407949 | ||
| Quinolones: action and resistance updated | Q37595559 | ||
| Plasmid-mediated quinolone resistance: an update. | Q37795644 | ||
| Resistance surveillance studies: a multifaceted problem--the fluoroquinolone example | Q37998398 | ||
| Plasmids and the spread of resistance | Q38090172 | ||
| Plasmid-mediated quinolone resistance--current knowledge and future perspectives | Q38097417 | ||
| The 4-quinolone antibiotics: past, present, and future | Q39314610 | ||
| Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser(83) and Asp(87). | Q39477717 | ||
| Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins | Q39478835 | ||
| DNA gyrase and topoisomerase IV are dual targets of clinafloxacin action in Streptococcus pneumoniae. | Q39559340 | ||
| Alteration in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV in quinolone-resistant clinical isolates of Staphylococcus epidermidis. | Q39559732 | ||
| Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones | Q39651324 | ||
| In vitro selection and characterization of Bacillus anthracis mutants with high-level resistance to ciprofloxacin | Q39776135 | ||
| Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell killing by fluoroquinolones. | Q39782108 | ||
| Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. | Q39782937 | ||
| Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones. | Q39783715 | ||
| A single point mutation in the DNA gyrase A protein greatly reduces binding of fluoroquinolones to the gyrase-DNA complex | Q39864841 | ||
| Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli | Q41788804 | ||
| Determination of the primary target of a quinolone drug and the effect of quinolone resistance-conferring mutations by measuring quinolone sensitivity based on its mode of action | Q41829994 | ||
| Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV | Q42111571 | ||
| Comparison of in vitro activities of fluoroquinolone-like 2,4- and 1,3-diones | Q42183775 | ||
| Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates | Q42234726 | ||
| Fluoroquinolone and quinazolinedione activities against wild-type and gyrase mutant strains of Mycobacterium smegmatis. | Q42727166 | ||
| Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones | Q43251107 | ||
| 1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS. | Q43498212 | ||
| Ciprofloxacin affects conformational equilibria of DNA gyrase A in the presence of magnesium ions | Q43685586 | ||
| The Glu-84 of the ParC subunit plays critical roles in both topoisomerase IV-quinolone and topoisomerase IV-DNA interactions | Q44148098 | ||
| Is plasmid-mediated quinolone resistance a clinically significant problem? | Q46812075 | ||
| The prevalence of the OqxAB multidrug efflux pump amongst olaquindox-resistant Escherichia coli in pigs | Q46854810 | ||
| Fluoroquinolone-modifying enzyme: a new adaptation of a common aminoglycoside acetyltransferase | Q46862305 | ||
| Topoisomerase IV catalysis and the mechanism of quinolone action | Q47891380 | ||
| New topoisomerase essential for chromosome segregation in E. coli | Q48251052 | ||
| DNA gyrase and topoisomerase IV: biochemical activities, physiological roles during chromosome replication, and drug sensitivities | Q50129292 | ||
| A novel family (QnrAS) of plasmid-mediated quinolone resistance determinant | Q53454705 | ||
| Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. | Q54060207 | ||
| Quinolone resistance from a transferable plasmid. | Q54143628 | ||
| Interaction of plasmid and host quinolone resistance | Q73167556 | ||
| Quinolones inhibit DNA religation mediated by Staphylococcus aureus topoisomerase IV. Changes in drug mechanism across evolutionary boundaries | Q73236875 | ||
| Roles of topoisomerases in maintaining steady-state DNA supercoiling in Escherichia coli | Q73538480 | ||
| Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds | Q74533257 | ||
| Structure-activity relationships of 3-aminoquinazolinediones, a new class of bacterial type-2 topoisomerase (DNA gyrase and topo IV) inhibitors | Q79463900 | ||
| Curing bacteria of antibiotic resistance: reverse antibiotics, a novel class of antibiotics in nature | Q83994271 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bacteria | Q10876 |
| quinolones | Q426549 | ||
| bacterial infectious disease | Q727028 | ||
| antibiotic | Q12187 | ||
| bacterial drug resistance | Q64924127 | ||
| P304 | page(s) | 1565-1574 | |
| P577 | publication date | 2014-03-07 | |
| 2014-03-18 | |||
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Mechanism of quinolone action and resistance | |
| P478 | volume | 53 |
| Q97074069 | (Fluoro)quinolones and quinolone resistance genes in the aquatic environment: A river catchment perspective |
| Q37204002 | A "Double-Edged" Scaffold: Antitumor Power within the Antibacterial Quinolone |
| Q49607587 | A Fluorescence-Based Assay for Identification of Bacterial Topoisomerase I Poisons |
| Q61813451 | A New Approach for Improving the Antibacterial and Tumor Cytotoxic Activities of Pipemidic Acid by Including It in Trimethyl-β-cyclodextrin |
| Q64093642 | A RADAR-Based Assay to Isolate Covalent DNA Complexes in Bacteria |
| Q90441022 | A Rapid ATP Bioluminescence-based Test for Detecting Levofloxacin Resistance Starting from Positive Blood Culture Bottles |
| Q42427707 | A cell cycle-controlled redox switch regulates the topoisomerase IV activity |
| Q52355825 | A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance. |
| Q59130616 | A review of antibiotic prophylaxis for traveler's diarrhea: past to present |
| Q89704957 | A slurry microcosm study on the interaction between antibiotics and soil bacterial community |
| Q47766774 | Activities of gyrase and topoisomerase IV on positively supercoiled DNA. |
| Q35592636 | Activity of quinolone CP-115,955 against bacterial and human type II topoisomerases is mediated by different interactions |
| Q59789451 | Adherent/invasive Escherichia coli (AIEC) isolates from asymptomatic people: new E. coli ST131 O25:H4/H30-Rx virotypes |
| Q103804774 | An in silico approach to analyze HCV genotype-specific binding-site variation and its effect on drug-protein interaction |
| Q64066297 | Analysis of Pooled Phase III Efficacy Data for Delafloxacin in Acute Bacterial Skin and Skin Structure Infections |
| Q55002498 | Analysis of antibiotics resistant genes in different strains of Staphylococcus aureus. |
| Q57490251 | Anthropogenic Impacts on Meiosis in Plants |
| Q90633118 | Antibacterial Effects of Quinazolin-4(3H)-One Functionalized-Conjugated Silver Nanoparticles |
| Q38399943 | Antibacterial small molecules targeting the conserved TOPRIM domain of DNA gyrase. |
| Q94400760 | Antibiotic prophylaxis for people with cirrhosis and variceal bleeding |
| Q94398502 | Antibiotic prophylaxis to prevent spontaneous bacterial peritonitis in people with liver cirrhosis: a network meta‐analysis |
| Q48326996 | Antibiotic resistance and repetitive-element PCR fingerprinting in Aeromonas veronii isolates. |
| Q91909978 | Antibiotic resistance in porcine pathogenic bacteria and relation to antibiotic usage |
| Q90122425 | Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta-analysis |
| Q94397745 | Antibiotic treatment for spontaneous bacterial peritonitis in people with decompensated liver cirrhosis: a network meta‐analysis |
| Q92421365 | Antibiotic-Induced Perturbations Are Manifested in the Dominant Intestinal Bacterial Phyla of Atlantic Salmon |
| Q57300031 | Antibiotics, Resistome and Resistance Mechanisms: A Bacterial Perspective |
| Q90308635 | Antimicrobial Resistance in Veterinary Medicine: An Overview |
| Q36075965 | Antimicrobial Susceptibility and SOS-Dependent Increase in Mutation Frequency Are Impacted by Escherichia coli Topoisomerase I C-Terminal Point Mutation. |
| Q52360303 | Antimicrobial resistance (AMR) nanomachines-mechanisms for fluoroquinolone and glycopeptide recognition, efflux and/or deactivation. |
| Q33654837 | Antimicrobial resistance and virulence characterization of Staphylococcus aureus and coagulase-negative staphylococci from imported beef meat. |
| Q92000710 | Antimicrobial resistance in nephrology |
| Q64078565 | Application of Antimicrobial Peptides of the Innate Immune System in Combination With Conventional Antibiotics-A Novel Way to Combat Antibiotic Resistance? |
| Q50045822 | Association of drug resistance of Mycoplasma pneumoniae with DNA load and genotypes in children with Mycoplasma pneumoniae pneumonia |
| Q34597404 | Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge |
| Q88981142 | Bacterial Cytological Profiling Reveals the Mechanism of Action of Anticancer Metal Complexes |
| Q58574331 | Baxdela (Delafloxacin): A Novel Fluoroquinolone for the Treatment of Acute Bacterial Skin and Skin Structure Infections |
| Q92947798 | Benchmark Dose Analysis of DNA Damage Biomarker Responses Provides Compound Potency and Adverse Outcome Pathway Information for the Topoisomerase II Inhibitor Class of Compounds |
| Q90739322 | Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV |
| Q37570567 | Characteristics of Quinolone Resistance in Escherichia coli Isolates from Humans, Animals, and the Environment in the Czech Republic |
| Q92051378 | Characterization of Mechanisms Lowering Susceptibility to Flumequine among Bacteria Isolated from Chilean Salmonid Farms |
| Q93353965 | Characterization of gyrA and parC mutations in ciprofloxacin-resistant Pseudomonas aeruginosa isolates from Tehran hospitals in Iran |
| Q58781056 | Characterizing Mobilized Virulence Factors and Multidrug Resistance Genes in Carbapenemase-Producing in a Sri Lankan Hospital |
| Q93343610 | Clinical features and seasonal variations in the prevalence of macrolide-resistant Mycoplasma pneumoniae |
| Q57821217 | Community-Acquired Urinary Tract Infection by in the Era of Antibiotic Resistance |
| Q40287467 | Comparative subproteomic analysis of clinically acquired fluoroquinolone resistance and ciprofloxacin stress in Salmonella Typhimurium DT104B. |
| Q91991771 | Compounding Effects of Climate Warming and Antibiotic Resistance |
| Q47819576 | Contaminants of emerging concern affect Trichoplusia ni growth and development on artificial diets and a key host plant. |
| Q36607637 | Crystal structure and stability of gyrase-fluoroquinolone cleaved complexes from Mycobacterium tuberculosis. |
| Q40442144 | Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide |
| Q64069079 | Current Perspectives on Treatment of Gram-Positive Infections in India: What Is the Way Forward? |
| Q90445964 | Cyclopropanation-ring expansion of 3-chloroindoles with α-halodiazoacetates: novel synthesis of 4-quinolone-3-carboxylic acid and norfloxacin |
| Q90258921 | DNA Damage Repair and Drug Efflux as Potential Targets for Reversing Low or Intermediate Ciprofloxacin Resistance in E. coli K-12 |
| Q91847145 | DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion |
| Q49607722 | DNA Topoisomerases as Targets for Antibacterial Agents |
| Q92186488 | DNA gyrase could be a crucial regulatory factor for growth and survival of Mycobacterium leprae |
| Q90256839 | DNA markers for tuberculosis diagnosis |
| Q39078552 | DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens. |
| Q39320242 | DNA topoisomerase-targeting chemotherapeutics: what's new? |
| Q40713954 | Design and evaluation of proniosomes as a carrier for ocular delivery of lomefloxacin HCl. |
| Q52319877 | Design, synthesis, and evaluation of novel N-1 fluoroquinolone derivatives: Probing for binding contact with the active site tyrosine of gyrase. |
| Q89907735 | Detection of Chromosomal and Plasmid-Mediated Quinolone Resistance Among Escherichia coli Isolated from Urinary Tract Infection Cases; Zagazig University Hospitals, Egypt |
| Q53687829 | Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria. |
| Q64062960 | DksA-RNA polymerase interactions support new origin formation and DNA repair in Escherichia coli |
| Q46237911 | Double-Serine Fluoroquinolone Resistance Mutations Advance Major International Clones and Lineages of Various Multi-Drug Resistant Bacteria |
| Q40475934 | Draft Genome Sequence of Enterococcus faecalis Strain F165 Isolated from a Urinary Tract Infection. |
| Q47141510 | Draft Genome Sequence of a Clinical Enterococcus faecium Sequence Type 18 Strain from South Africa |
| Q64941577 | Effects of Lysozyme on the Activity of Ionic of Fluoroquinolone Species. |
| Q52579373 | Emerging treatment options for acute bacterial skin and skin structure infections: focus on intravenous delafloxacin. |
| Q28822179 | Endless Resistance. Endless Antibiotics? |
| Q40653236 | Enhancement of lomefloxacin Hcl ocular efficacy via niosomal encapsulation: in vitro characterization and in vivo evaluation. |
| Q90330819 | Essential Guide of Analysis Methods Applied to Silver Complexes with Antibacterial Quinolones |
| Q52684515 | Evidence for Inhibition of Topoisomerase 1A by Gold(III) Macrocycles and Chelates Targeting Mycobacterium tuberculosis and Mycobacterium abscessus. |
| Q92942843 | Examining the Impact of Antimicrobial Fluoroquinolones on Human DNA Topoisomerase IIα and IIβ |
| Q64099161 | Exploitation of Antibiotic Resistance as a Novel Drug Target: Development of a β-Lactamase-Activated Antibacterial Prodrug |
| Q46791060 | First Report of a Whole-Genome Shotgun Sequence of a Clinical Enterococcus faecalis Sequence Type 6 Strain from South Africa |
| Q36607348 | Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase |
| Q57945279 | Fluoroquinolone resistance in Salmonella: insights by whole-genome sequencing |
| Q64065419 | Fluoroquinolone-Resistant , spp., and from Local and Imported Poultry Meat in Kumasi, Ghana |
| Q50048891 | Fluoroquinolones as imaging agents for bacterial infection |
| Q38975466 | Functional Characterization of the DNA Gyrases in Fluoroquinolone-Resistant Mutants of Francisella novicida |
| Q40474955 | Genomic analysis of the multi-drug-resistant clinical isolate Myroides odoratimimus PR63039. |
| Q91721708 | Genotypic and phenotypic profiles of virulence factors and antimicrobial resistance of Proteus mirabilis isolated from chicken carcasses: potential zoonotic risk |
| Q60922671 | High frequency of mutations in gene associated with quinolones resistance in uropathogenic isolates from the north of Iran |
| Q58778215 | Identification by virtual screening and functional characterisation of novel positive and negative allosteric modulators of the α7 nicotinic acetylcholine receptor |
| Q52841793 | Identification of a novel qnrA allele, qnrA8, in environmental Shewanella algae. |
| Q91897802 | Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus |
| Q93083428 | Identification of an auxiliary druggable pocket in the DNA gyrase ATPase domain using fragment probes |
| Q53407262 | In vitro Antibacterial Activity of 7-Substituted-6-Fluoroquinolone and 7-Substituted-6,8-Difluoroquinolone Derivatives. |
| Q38761164 | In vitro biological evaluation of novel broad-spectrum isothiazolone inhibitors of bacterial type II topoisomerases. |
| Q41990188 | Ingestion of the anti-bacterial agent, gemifloxacin mesylate, leads to increased gst activity and peroxidation products in hemolymph of Galleria mellonella l. (lepidoptera: pyralidae). |
| Q41120230 | Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914. |
| Q55500169 | Inter-Laboratory Validation of Method to Determine Residual Enrofloxacin in Chicken Meat. |
| Q46335874 | Interactions between Quinolones and Bacillus anthracis Gyrase and the Basis of Drug Resistance |
| Q40067159 | Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries. |
| Q89113641 | Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site |
| Q26780246 | Investigational drugs to treat methicillin-resistant Staphylococcus aureus |
| Q94548290 | Lead Identification of 8-(Methylamino)-2-oxo-1,2-dihydroquinoline Derivatives as DNA Gyrase Inhibitors: Hit-to-Lead Generation Involving Thermodynamic Evaluation |
| Q92533197 | Levonadifloxacin, a Novel Broad-Spectrum Anti-MRSA Benzoquinolizine Quinolone Agent: Review of Current Evidence |
| Q92682023 | Ligands and Receptors with Broad Binding Capabilities Have Common Structural Characteristics: An Antibiotic Design Perspective |
| Q64100833 | Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract |
| Q90424133 | Lying in Wait: Modeling the Control of Bacterial Infections via Antibiotic-Induced Proviruses |
| Q60732945 | Mechanism of Action of Mycobacterium tuberculosis Gyrase Inhibitors: A Novel Class of Gyrase Poisons |
| Q55387439 | Mechanisms of Antibiotic Resistance. |
| Q36225422 | Mechanisms of drug resistance: quinolone resistance |
| Q64085348 | Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase |
| Q39418003 | Mitochondrial dysfunction and potential anticancer therapy. |
| Q55407405 | Modifications of quinolones and fluoroquinolones: hybrid compounds and dual-action molecules. |
| Q40151282 | Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b. |
| Q47247464 | Molecular viability testing of viable but non-culturable bacteria induced by antibiotic exposure. |
| Q92755899 | Multicenter Clinical Evaluation of a Novel Multiplex Real-Time PCR (qPCR) Assay for Detection of Fluoroquinolone Resistance in Mycoplasma genitalium |
| Q50062555 | Multifaceted Supramolecular Interactions from C-Methylresorcin[4]arene Lead to an Enhancement in In Vitro Antibacterial Activity of Gatifloxacin |
| Q41686050 | Mutant prevention concentrations of levofloxacin, pazufloxacin and ciprofloxacin for A. baumannii and mutations in gyrA and parC genes |
| Q58613928 | N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluation |
| Q36153263 | New Structural Templates for Clinically Validated and Novel Targets in Antimicrobial Drug Research and Development. |
| Q91807571 | New tuberculosis drug targets, their inhibitors, and potential therapeutic impact |
| Q93226328 | Non-clinical isolates as potential reservoirs of antibiotic resistance in Port Harcourt, Nigeria |
| Q43174723 | Not All Antibiotic Use Practices in Food-Animal Agriculture Afford the Same Risk |
| Q48105075 | Novel Bacterial Topoisomerase Inhibitors Exploit Asp83 and the Intrinsic Flexibility of the DNA Gyrase Binding Site. |
| Q52629698 | Novel Ciprofloxacin-Modifying Enzyme (CrpP) Encoded by the Pseudomonas aeruginosa pUM505 Plasmid. |
| Q41813552 | Novobiocin Inhibits the Antimicrobial Resistance Acquired through DNA Damage-Induced Mutagenesis in Acinetobacter baumannii. |
| Q64109392 | Occurrence and characterization of quinolone resistant Escherichia coli from Norwegian turkey meat and complete sequence of an IncX1 plasmid encoding qnrS1 |
| Q54237618 | Our Evolving Understanding of the Mechanism of Quinolones. |
| Q91940578 | Overview of methicillin resistant Staphylococcus aureus mediated bone and joint infections in India |
| Q90636536 | Palmatine Is a Plasmid-Mediated Quinolone Resistance (PMQR) Inhibitor That Restores the Activity of Ciprofloxacin Against QnrS and AAC(6')-Ib-cr-Producing Escherichia coli |
| Q92978562 | Pathogenomics and Evolutionary Epidemiology of Multi-Drug Resistant Clinical Klebsiella pneumoniae Isolated from Pretoria, South Africa |
| Q89496296 | Phenotypic and molecular characterization of antimicrobial resistant Escherichia coli from urinary tract infections in Port-Harcourt, Nigeria |
| Q36913948 | Polyphosphate Kinase Mediates Antibiotic Tolerance in Extraintestinal Pathogenic Escherichia coli PCN033 |
| Q38816087 | Preparation of Thermosensitive Gel for Controlled Release of Levofloxacin and Their Application in the Treatment of Multidrug-Resistant Bacteria. |
| Q40275335 | Prevalence and Antimicrobial Susceptibility of Enterobacteriaceae Isolated from Retail Pepper in Vietnam |
| Q50952423 | Prevalence and Mechanism of Fluoroquinolone Resistance in Escherichia coli Isolated from Swine Feces in Korea. |
| Q47123962 | Prevalence and characteristics of ST131 clone among unselected clinical Escherichia coli in a Chinese university hospital |
| Q40559404 | Prevalence of Quinolone Resistance in Enterobacteriaceae from Sierra Leone and the Detection of qnrB Pseudogenes and Modified LexA Binding Sites |
| Q36158288 | Protective effect of Qnr on agents other than quinolones that target DNA gyrase |
| Q38817697 | Quinazolinone azolyl ethanols: potential lead antimicrobial agents with dual action modes targeting methicillin-resistant Staphylococcus aureus DNA. |
| Q90433589 | Quinolone Complexes with Lanthanide Ions: An Insight into their Analytical Applications and Biological Activity |
| Q91709476 | Quinolone antibiotics |
| Q40247693 | Quinolone resistance-associated amino acid substitutions affect enzymatic activity of Mycobacterium leprae DNA gyrase |
| Q92431372 | Quinolone-isoniazid hybrids: synthesis and preliminary in vitro cytotoxicity and anti-tuberculosis evaluation |
| Q55646811 | Quinolones Modulate Ghrelin Receptor Signaling: Potential for a Novel Small Molecule Scaffold in the Treatment of Cachexia. |
| Q47758933 | RNase H1 Cooperates with DNA Gyrases to Restrict R-Loops and Maintain Genome Integrity in Arabidopsis Chloroplasts |
| Q42261392 | Recognition of DNA Supercoil Geometry by Mycobacterium tuberculosis Gyrase. |
| Q46655216 | Relative contribution of biological variation and technical variables to zone diameter variations of disc diffusion susceptibility testing |
| Q91902694 | Resistance and Virulence Mechanisms of Escherichia coli Selected by Enrofloxacin in Chicken |
| Q64257116 | Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis |
| Q35848139 | Responding to the challenge of untreatable gonorrhea: ETX0914, a first-in-class agent with a distinct mechanism-of-action against bacterial Type II topoisomerases. |
| Q58701297 | Resurrection of Nalidixic Acid: Evaluation of Water-Based Nanoformulations as Potential Nanomedicine |
| Q34119765 | Role of the water-metal ion bridge in mediating interactions between quinolones and Escherichia coli topoisomerase IV. |
| Q92272240 | Salmonellosis detection and evidence of antibiotic resistance in an urban raccoon population in a highly populated area, Costa Rica |
| Q89985224 | Sensing Living Bacteria in Vivo Using d-Alanine-Derived 11C Radiotracers |
| Q51745466 | Simultaneous quantification of gatifloxacin, moxifloxacin, and besifloxacin concentrations in cornea and aqueous humor by LC-QTOF/MS after topical ocular dosing. |
| Q35999091 | Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents |
| Q40239631 | Structural basis of DNA gyrase inhibition by antibacterial QPT-1, anticancer drug etoposide and moxifloxacin. |
| Q40066931 | Subproteomic signature comparison of in vitro selected fluoroquinolone resistance and ciprofloxacin stress in Salmonella Typhimurium DT104B. |
| Q64105152 | Substantial Contribution of SmeDEF, SmeVWX, SmQnr, and Heat Shock Response to Fluoroquinolone Resistance in Clinical Isolates of Stenotrophomonas maltophilia |
| Q36817994 | Suppression of gyrase-mediated resistance by C7 aryl fluoroquinolones. |
| Q77396578 | Synergistic Effects of Anionic/Cationic Dendrimers and Levofloxacin on Antibacterial Activities |
| Q53059729 | Synthesis and Characterization of Magnetic Molecularly Imprinted Polymer for the Enrichment of Ofloxacin Enantiomers in Fish Samples. |
| Q38743645 | Synthesis of first ever 4-quinolone-3-carboxylic acid-appended spirooxindole-pyrrolidine derivatives and their biological applications |
| Q90170383 | Synthetic studies on the reverse antibiotic natural products, the nybomycins |
| Q40676412 | Targeted next-generation sequencing for the detection of ciprofloxacin resistance markers using molecular inversion probes. |
| Q35558361 | Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics |
| Q38855273 | Targeting bacterial topoisomerases: how to counter mechanisms of resistance |
| Q38878252 | Tavaborole - a treatment for onychomycosis of the toenails |
| Q91581288 | The C7-aminomethylpyrrolidine group rescues the activity of a thio-fluoroquinolone |
| Q58777518 | The Culture Environment Influences Both Gene Regulation and Phenotypic Heterogeneity in |
| Q26752640 | The Current Case of Quinolones: Synthetic Approaches and Antibacterial Activity |
| Q92633491 | The Microbial Toxin Microcin B17: Prospects for the Development of New Antibacterial Agents |
| Q41297677 | The Role of the MAPK Signaling, Topoisomerase and Dietary Bioactives in Controlling Cancer Incidence |
| Q40250981 | The antibacterial agent, moxifloxacin inhibits virulence factors of Candida albicans through multitargeting |
| Q94452257 | The challenge of intracellular antibiotic accumulation, a function of fluoroquinolone influx versus bacterial efflux |
| Q38579512 | The emerging threat of multidrug-resistant Gram-negative bacteria in urology. |
| Q64109231 | The nature and epidemiology of OqxAB, a multidrug efflux pump |
| Q64886146 | Therapeutic Contact Lenses with Polymeric Vehicles for Ocular Drug Delivery: A Review. |
| Q33782498 | Thiophene antibacterials that allosterically stabilize DNA-cleavage complexes with DNA gyrase |
| Q38906198 | Topoisomerase Inhibitors: Fluoroquinolone Mechanisms of Action and Resistance |
| Q49832269 | Topoisomerases as anticancer targets |
| Q33726354 | Unique Features of Aeromonas Plasmid pAC3 and Expression of the Plasmid-Mediated Quinolone Resistance Genes |
| Q28083890 | Use of ciprofloxacin during breastfeeding |
| Q47720108 | VIVO complexes with antibacterial quinolone ligands and their interaction with serum proteins |
| Q91511877 | WQ-3810: A new fluoroquinolone with a high potential against fluoroquinolone-resistant Mycobacterium tuberculosis |
| Q92430058 | Watching DNA Replication Inhibitors in Action: Exploiting Time-Lapse Microfluidic Microscopy as a Tool for Target-Drug Interaction Studies in Mycobacterium |
| Q47736241 | What Is Old Is New Again: Delafloxacin, a Modern Fluoroquinolone |
| Q55215658 | Wicked: The untold story of ciprofloxacin. |
Search more.